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Abstract
Aims To analyse the association between coeliac disease (CD) and depression in children, adolescents, and young adults 
with type 1 diabetes (T1D).
Methods We included 79,067 T1D patients aged 6–20 years, with at least six months of diabetes duration, and treatment 
data between 1995 and 2019 were documented in the diabetes patient follow-up registry. We categorized patients into four 
groups: T1D only (n = 73,699), T1 + CD (n = 3379), T1D + depression (n = 1877), or T1D + CD + depression (n = 112).
Results CD and depression were significantly associated (adjusted OR: 1.25 [1.03–1.53]). Females were more frequent in 
both the depression and the CD group compared with the T1D only group. Insulin pumps were used more frequently in 
T1D + CD and T1D + depression compared with T1D only (both p < .001). HbA1c was higher in T1D + depression (9.0% 
[8.9–9.0]), T1D + CD + depression (8.9% [8.6–9.2]), both compared with T1D only (8.2% [8.2–8.2], all p < .001). We found 
comorbid autism, attention deficit hyperactivity disorder, anxiety, schizophrenia, and eating disorders more frequently in 
the T1D + CD + depression group compared with T1D only (all p < .001).
Conclusions CD and depression are associated in young T1D patients. The double load of T1D and CD may lead to an 
increased risk for depression. Depression was associated with additional psychological and neurological comorbidities. Aside 
from imperative CD screening after T1D diagnosis and regular intervals, depression screening might be helpful in routine 
care, especially in patients with diagnosed CD.
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Introduction
Coeliac disease (CD) is an autoimmune-mediated disorder 
resulting in intestinal damage and mucosal atrophy on con-
sumption of gluten [1]. CD is a common comorbidity in 
type 1 diabetes (T1D) with an average prevalence of approx. 
5% versus 1% in the general population [2]. In an interna-
tional comparison of children and adolescents with T1D, 
CD prevalence has been reported to range between 1.6% and 
16.4% [3]. Prevalence of CD is increasing, even in regions 
like Asia, where gluten is now consumed more frequently 
due to changes in eating habits and infant feeding [4].
The first description of CD was given by Samuel Gee in 
1888, suggesting dietary treatment; however, wheat, rye, and 
oats as toxic components were not identified until 1950 [5]. 
Earlier publications discussing CD and behavioural abnor-
malities presented case reports of phlegmatic, “difficult,” or 
“naughty” infants and children with overall bad behaviour, 
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crying attacks of unknown reasons during the night, low appe-
tite, and general negativity [6, 7], which improved after initia-
tion of a gluten-free diet (GFD).
Guidelines by the European Society for the Study of Coe-
liac Disease recommend duodenal biopsies for CD diagnosis 
in adults [8], especially if patients have pre-existing T1D, fam-
ily history of CD, or other associated comorbidities [9]. CD 
in adults is often associated with concomitant extra-intestinal 
symptoms including anxiety, depression, thoughts of self-
harm, dementia, epilepsy, attention deficit hyperactivity dis-
order (ADHD), autism, eating disorders, infertility, and others 
[10–17].
However, not every patient with CD experiences symptoms 
[18]. As a genetic component of CD has been recognized, 
family members of CD patients are often screened before 
symptoms occur [19, 20]. The recent ESPGHAN guidelines 
postulate antibody testing in all suspected CD cases with sub-
sequent biopsy in case the antibody titers are not more than 
10 times the upper limit of the reference range [1]. Based on 
the increased prevalence of CD in T1D, the ISPAD guidelines 
also recommend CD screening at diagnosis of T1D and at 2 
and 5 years thereafter [17]. The multinational TEDDY study 
focused on genetic and environmental risk factors for T1D 
and CD in newborns and infants that showed typical HLA 
haplotypes [21].
Until today, the only way to treat CD and prevent symptoms 
is via strict GFD, since even the smallest amounts of gluten 
can cause the onset or aggravation of CD symptoms [12]. By 
diagnosing CD and strictly adhering to a GFD, the occurrence 
of symptoms can be prevented.
According to the World Health Organization (WHO), the 
global prevalence of depressive disorders in children and ado-
lescents ranges from 3–4.5% [22]. In young T1D patients, the 
prevalence of depression ranges from 15 to 30% [23–25].
The treatment of T1D, CD, and depression all requires 
different knowledge in the respective treatment and there-
fore a multidisciplinary team. To our knowledge, there are 
no studies about the combined occurrence of depression 
and CD in paediatric and young adult T1D patients. Our 
aim is to fill that gap and compare young T1D patients with 
CD and/or depression to T1D patients with neither CD nor 
depression, investigating demographic and therapy-related 
outcomes. In addition, we assessed possible associations 




We included patients from the diabetes prospective follow-
up registry (DPV) that fulfilled the following criteria: (1) 
T1D diabetes onset at age ≥ 6 months, (2) age 6–20 years, 
(3) at least 6 months of diabetes duration, and (4) treat-
ment data available between January 1995 and December 
2019.
DPV is a multicentre initiative comprising 588,860 dia-
betes patients (March 2020) and 501 centres in Germany, 
Austria, Switzerland, and Luxembourg. In total, 476 centres 
contributed data to this analysis. More than 90% of paediat-
ric T1D patients in Germany are estimated to be documented 
in the DPV [2]. Data collection and analysis of anonymized 
data from the DPV registry were approved by the Medical 
Faculty Ethics Committee of Ulm University, Germany, and 
by the local review boards of participating centres. Semi-
annually, centres send pseudonymized data to Ulm, Ger-
many, where data are validated, anonymized, and added to 
the cumulative database [2].
We assigned patients to mutually exclusive groups: T1D 
only, T1D + CD, T1D + depression, or T1D + CD + depres-
sion based on all observed data from that patient in the DPV. 
T1D only was our reference group.
Variables
CD diagnosis was based on clinical diagnosis (in part based 
on antibody results) by the treatment centre, with or with-
out confirmation by small bowel biopsy. Depression was 
defined by clinical diagnosis (ICD10 and DSM-V) or spe-
cific pharmacotherapy [26]. Demographic data were age, 
diabetes duration, age at diabetes diagnosis, sex, and migra-
tion background (at least one parent or patient not born in 
Germany, Austria, Switzerland, or Luxembourg). Outcomes 
of interest were BMI-SDS, HbA1c, type of insulin therapy 
(injection vs. pump therapy), severe hypoglycaemia, diabetic 
ketoacidosis (DKA), and psychological/neurological comor-
bidities including autism, ADHD, schizophrenia, anxieties, 
and eating disorders (anorexia, bulimia, binge eating, oth-
ers). Psychological and neurological comorbidities were 
documented by appropriate diagnosis terms or ICD10 codes 
by experienced psychologists that are present in every certi-
fied diabetes centres participating in DPV. We also analysed 
microalbuminuria (defined by urine albumin-to-creatinine 
ratio ≥ 30 mg/g) and retinopathy. Patients with missing infor-
mation on retinopathy or nephropathy were excluded from 
the respective analysis only. HbA1c was standardized to the 
reference range of 4.05%—6.05% according to the Diabetes 
Control and Complication Trial (DCCT) using the multi-
ple of the mean method [2]. For BMI-SDS values, we used 
AGA (German paediatric obesity working group) reference 
data [27]. We defined severe hypoglycaemia as hypogly-
caemic episode with cognitive impairment (with or without 
coma) necessitating help from another person [2]. DKA was 
defined as pH < 7.3 and/or serum bicarbonate < 15 mmol/l.
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Data aggregation
We aggregated data as medians for all records during the 
most recent treatment year of each patient. Depression, 
CD, and psychological comorbidities were aggregated per 
lifetime.
Statistical methods
In the unadjusted analysis of demographic and clinical vari-
ables (Table 1), medians and interquartile ranges (IQR) are 
presented for continuous variables and percentages for cat-
egorical variables. We used Wilcoxon’s rank-sum test for 
unadjusted group comparisons of continuous variables and 

2-test for categorical variables. Two-sided p-values were 
adjusted for multiple testing according to Bonferroni–Holm, 
and significance was set at < 0.05. For HbA1c and BMI-
SDS, we used linear regression models and reported out-
comes as adjusted least-square means [95% confidence inter-
val (CI)], and logistic models for the association of CD with 
depression (odds ratio with 95% CI), and the frequency of 
other comorbidities (least-square mean with 95% CI). Severe 
hypoglycaemia or DKA rates per patient-year (least-square 
mean with 95% CI) were calculated using negative binomial 
regression models with individual time under risk as offset. 
All regression models were adjusted for sex, age group, age 
at diabetes onset group, and migration background. Age 
was categorized as 6–12, > 12–18, > 18–20 years and age at 
diabetes onset as ≤ / > 10 years. For sensitivity analysis, we 
adjusted the microalbuminuria and retinopathy models addi-
tionally for HbA1c groups (≤ / > 7.5% (58.5 mmol/mol)).
Results
Among 79,067 T1D patients, 1,877 (2.4%) had comorbid 
depression, 3,379 (4.3%) had CD (62.2% biopsy-proven), 
and 112 (0.1%) patients had CD and depression (65.2% 
biopsy-proven). T1D only was found in 73,699 (93.2%). 
We found a significant association between CD and depres-
sion (adjusted OR: 1.25 [1.03–1.53]). For sensitivity analy-
sis, we calculated the same model with biopsy-proven CD 
only, where the association was not significant (OR: 1.26 
[0.99–1.60]).
Patients with T1D + CD were younger, and patients 
with T1D + depression (with or without additional CD) 
were older compared to the reference group (all p < 0.001, 
Table 1). We found an imbalance regarding sex distribution 
in all comorbidity groups. (Females were more common in 
the three CD/depression groups compared with the reference 
Table 1  Characteristics of T1D patients during most recent treatment year
Data are presented as median [interquartile range] or as percentage
p-values were adjusted for multiple testing
CD Coeliac disease, D depression, T1D type 1 diabetes
Total T1D + CD + D T1D + CD T1D + D T1D only p-value T1D 
only versus 









79,067 112 3379 1877 73,699
Male sex [%] 52.8 34.8 44.3 42.7 53.5 < .001 < .001 < .001










< .001 < .001 < .001
Diabetes dura-
tion [y]




8.9 [5.5–12.1] 7.7 [4.0–11.4] 6.2 [3.4–9.8] 10.1 
[6.7–12.7]
9.0 [5.6–12.1] .11 < .001 < .001
Pump therapy 
[%]












17.4 24.1 18.9 17.8 17.3 .12 .03 .60
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group (all p < 0.001).) There were no significant differ-
ences in the proportions of patients with migration back-
ground between the groups, except in T1D + CD compared 
with T1D only (18.9% vs. 17.3%, p = 0.03). Pump usage 
was more frequent in T1D + CD and in T1D + depression 
patients (both p < 0.001) compared with the reference group 
(Table 1).
T1D + CD patients had a lower adjusted BMI-SDS (0.36 
[0.33–0.40]) compared with T1D only (0.52 [0.51–0.53]) 
and T1D + depression patients (0.55 [0.51–0.60], all 
p < 0.001). There was no difference between T1D + CD and 
T1D + CD + depression in BMI-SDS. T1D + depression 
with or without CD was associated with worse metabolic 
control compared with T1D only (both p < 0.001, Fig. 1). 
We found higher rates of DKA in T1D + depression patients 
compared to the reference group and higher rates of severe 
hypoglycaemia in T1D + depression and T1D + CD com-
pared with the reference group (Fig. 2).
Microalbuminuria was more frequent in patients with 
T1D + CD + depression (Fig.  3a). Adjusting for HbA1c 
did not have an impact on this result. Retinopathy occurred 
more often in T1D + depression compared with the reference 
group, even after HbA1c adjustment (Fig. 3b). In patients 
with T1D + depression with or without CD, we found higher 
rates of autism or ADHD (Fig. 3c, d), as well as anxiety, 
schizophrenia, or eating disorders (Fig. 3e, f, g) compared 
with the reference group.
Discussion
We found a positive association between CD and depression 
among children and young adults with T1D. In the general 
population, CD is associated with psychological disorders, 
such as depression [12], with a lifetime prevalence of up 
to 31% in CD patients compared with 7% of patients with-
out CD [28]. Our study confirms this association for usu-
ally asymptomatic CD in patients with T1D. Causes might 
include excessive cytokine secretion, or iron deficiency from 
malabsorption, reducing dopamine levels [12, 29, 30]. Early 
detection of CD is important, since adhering to a GFD may 
alleviate depressive symptoms [12, 31, 32]. Having T1D 
and additional CD is a heavier burden than having only one 
chronic disease. If we assume that depression develops later 
than CD, it is not surprising that the double load may lead 
to an increased risk for depression. However, we cannot say 
whether the increased risk for depression in CD is due to a 
restricted diet or due to untreated CD.
In particular, young patients with CD without T1D may 
experience exclusion from everyday life or bullying due to 
Fig. 1  Estimated HbA1c adjusted for age, age at diabetes onset, sex, 
migration background, treatment year. T1D: type 1 diabetes; CD: 
coeliac disease. p-values: ** < .001 95% confidence intervals
Fig. 2  Estimated event rates for glycaemic decompensation adjusted for age, age at diabetes onset, sex, migration background, treatment year. 
T1D: type 1 diabetes; CD: coeliac disease. a: severe hypoglycaemia, b: diabetic ketoacidosis (DKA). p-values: * < .05; ** < .001
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being different or the special diet they have to adhere to 
[33, 34]. Psychosocial distress may also derive from costs 
or availability of gluten-free food [35]. Since lifelong adher-
ence to a GFD is a difficult task, it is to argue whether adher-
ing to a strict diet in patients with only light symptoms and 
positive CD antibodies is preferable, or whether this has 
negative psychological effects. There exist conflicting data 
on a possible benefit of GFD in patients with only light or 
no symptoms [36, 37]. While there are reports of improved 
quality of life after GFD initiation, some report negative 
feelings in patients with GFD and reduced pleasure con-
cerning meals, and even higher rates of depression [12, 38].
Eating disorders have a known association with T1D as 
well as with CD and depression [12, 39]. Comorbid eating 
disorders or incomplete adherence to a GFD may lead to 
a lower BMI in CD due to malabsorption. It is difficult to 
objectively assess adherence to a GFD; however, constantly 
positive anti-transglutaminase antibodies are indicative. Our 
CD patients had a lower BMI-SDS compared with the T1D 
only group, which is in line with previous reports [2]. Eat-
ing disorders, however, were not more frequently observed 
in CD patients in our data. In contrast, patients with CD are 
reported to have a higher BMI due to potentially higher fat 
and caloric uptake [40] or due to adolescents possibly choos-
ing quickly available gluten-free snacks instead of healthy 
alternatives [41].
The lower BMI-SDS in T1D + CD patients (with-
out depression) could also hint at healthier eating habits, 
although glycaemic control was not significantly better com-
pared with the T1D only group. Patients with T1D + depres-
sion (with or without CD), on the other hand, had worse 
glycaemic control compared with T1D only, also result-
ing in higher rates of severe hypoglycaemia and DKA for 
patients with T1D + depression. Depression in T1D is known 
to affect adherence to insulin treatment, leading to worse 
metabolic outcome, higher rates of glycaemic decompensa-
tion, and more hospital admissions [24]. ISPAD guidelines 
also suggest investigating possible eating disorders in T1D 
patients with worse metabolic control and a multidiscipli-
nary team with a specialist paediatric dietician [3].
Higher frequencies of anxiety and/or depression in ado-
lescent T1D patients are well established. In our study, 
depression was diagnosed overall in only 2.5%, which is far 
less than the previously reported 12–30% of adolescents and 
young adults [23, 25, 42]. Therefore, one might conclude 
that depression is less frequent in younger T1D patients, 
which we included in this study. On the other hand, routine 
depression screening in diabetes centres is not (yet) estab-
lished and patients with depression might be missed if only 
clinically diagnosed patients are recorded. This could be a 
reason for the lower frequency of depression in our cohort.
Patients with depression were older compared with the 
reference group. Depression might require a certain stage 
of mental development to occur or to allow diagnosis, as 
diagnosing depression in young children is difficult [43]. 
As reported before, CD patients were younger compared 
with the reference group, implying a greater risk of CD in 
patients with earlier T1D onset [2]. Early screening for CD 
and depression in T1D patients may help improve quality of 
life and prevent consequences of undetected comorbidity.
As stated earlier, CD has been reported to be associated 
with a number of neurological and psychiatric comorbidi-
ties such as ADHD, autism, anxiety, and schizophrenia [12]. 
Interestingly, in our cohort none of these comorbidities were 
significantly more frequent in CD patients compared with 
the T1D only group. However, all of these were significantly 
more frequent in patients with depression (with or without 
additional CD). Depression is known to be associated with 
other psychiatric comorbidities and even with conditions 
such as autism [44].
In our registry, CD was diagnosed in 4.4% of patients, 
either via biopsy or via clinical diagnosis, which is in line 
with previous reports [2, 45]. 62.2% of our CD patients had 
biopsy-proven CD. According to several guidelines [1, 17], 
among other autoimmune diseases, paediatric patients with 
T1D are recommended to be screened for CD autoantibod-
ies, since links between T1D and CD are well known [2] 
and attributed to their common HLA haplotype DR3-DQ2 
or DR4-DQ8 [46]. Until recently, guidelines recommended 
duodenal biopsies at multiple sites to confirm CD in asymp-
tomatic patients [8, 17].
There is still no definitive statement on whether there is 
an association between sex and CD [2]. However, female sex 
is widely known to be associated with autoimmune diseases 
in general, though for yet unknown reasons [47]. Our find-
ings imply an association of female sex and both CD and 
depression. Charles et al. suggested a 2:1 ratio of females to 
males concerning mental health disorders [43], which is sim-
ilar in our patients with CD and depression (65.2% female). 
Therefore, we suggest that especially female patients should 
be screened for CD or signs of depression.
Major strengths of this study include the big sample 
size of paediatric T1D patients from different European 
countries and the representative nature of the DPV reg-
istry for young T1D patients in Germany, Austria, and 
Luxemburg. One weakness that is inherent to the investi-
gated question is the dependence on observational studies; 
therefore, causality between CD and depression cannot be 
proved. We are also unable to make statements about the 
prevalence of depression and CD in the registered patients 
due to possible underreporting. Validated questionnaires 
on depression such as the PHQ-9 were not available for 
our analysis. We do not have information on adherence 
to a GFD, so we could not analyse possible differences in 
outcomes between patients adhering to a GFD and patients 
that did not. Since ethnicity is not a suitable concept in 
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Germany, we used migration background as a covariate 
instead. Finally, since DPV is a diabetes registry we do not 
have data on patients with CD but without T1D to analyse 
the incidence of depression in CD patients compared to 
healthy controls. However, a recent study found an anxiety 
prevalence of 62.7% and depression prevalence of 34.9% 
in CD patients [48].
Conclusion
Depression is disproportionately more frequent in young 
T1D patients with additional CD. Aside from the recom-
mended CD screening at T1D diagnosis and in regular 
intervals thereafter, as suggested by several guidelines, 
depression screening can be helpful in routine care, espe-
cially in patients with diagnosed CD. Interdisciplinary 
cooperation between diabetologists, psychologists, and 
gastroenterologists should be promoted.
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